Prevalence of Pre - Extensively Drug Resistance Tuberculosis (Pre XDR-TB) & Extensively Drug Resistance Tuberculosis (XDR-TB) among Pulmonary Multidrug Resistance Tuberculosis at a Tertiary Care Hospital, Jamnagar

Main Article Content

Dipali Gavali
Binita Aring
Hiral Gadhavi
Akhlakahemad Nathamehta
Abhishek Dave
Aanand Nakhva

Abstract

Aims and Objective: Many diseases have a high prevalence in India, accounting for one-fourth of the Tuberculosis (TB) cases in the world. In our study, we aimed to find the prevalence of Pre XDR-TB and XDR-TB amongst newly diagnosed cases of pulmonary MDR-TB who had never been previously treated with second-line drugs. A prospective study was conducted in Culture and Drug susceptibility testing laboratory, Jamnagar and its associated Drug-Resistant Tuberculosis (DR-TB) centre.

Materials and Methods: Baseline second-line liquid culture DST has been recently integrated with the Revised National Tuberculosis Control Programme (RNTCP) diagnostic algorithm. We included 500 patients who were diagnosed in cases of pulmonary MDR-TB never exposed to second-line TB-Drugs. Mycobacterial Growth Indicator Tube method conducted in an RNTCP accredited Culture and Drug susceptibility testing laboratory, Jamnagar, as part of the evaluation in the public healthcare system from where patients were referred for diagnosis to us.

Results: 585 MDR suspected sputum samples were received, 466 sputum samples were showing culture positive for acid-fast bacilli which were screened against second-line drug susceptibility testing by using of BACTEC MGIT 960 (MGIT 960) instrument. About 293 Mycobacterium samples were MDR-TB, 151 were Pre- XDR TB and 22 were XDR-TB.

Conclusion: The prevalence of Pre XDR-TB and XDR-TB among MDR-TB patients were 32.4% and 4.7% respectively. The high prevalence of Pre XDR-TB (FQ) is alarming and of concern in the management of MDR-TB control in Jamnagar area.

Keywords:
Drug-resistant, tuberculosis, tertiary care hospital, mycobacterial growth.

Article Details

How to Cite
Gavali, D., Aring, B., Gadhavi, H., Nathamehta, A., Dave, A., & Nakhva, A. (2019). Prevalence of Pre - Extensively Drug Resistance Tuberculosis (Pre XDR-TB) & Extensively Drug Resistance Tuberculosis (XDR-TB) among Pulmonary Multidrug Resistance Tuberculosis at a Tertiary Care Hospital, Jamnagar. Journal of Advances in Microbiology, 19(2), 1-9. https://doi.org/10.9734/jamb/2019/v19i230186
Section
Original Research Article

References

Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57-72.
DOI: 10.1016/S0140-6736(10)621733
PMID: 21420161

Rothschild BM, Martin LD, Lev G, et al. Mycobacterium tuberculosis complex DNA from an extinct bison dated 17,000 years before the present. Clin. Infect. Dis. 2001;33(3):305-11.
DOI: 1086/321886
PMID: 11438894

Pearce-Duvet J. The origin of human pathogens: Evaluating the role of agriculture and domestic animals in the evolution of human disease. Biol Rev Camb Philos Soc. 2006;81(3):369-82.
DOI: 10.1017/S1464793106007020
PMID: 16672105

Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: Functional genetic analysis of gyrA and gyrB mutations. Plos One. 2012;7(6):e39754.

Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, Maryandyshev AO, Shemyakin IG, Kurbatova E, Cegielski JP. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk oblast, Russia, 2005-2010. Emerg Infect Dis. 2015;21(6):1002–11.

Jain A, Dixit P, Prasad R. Pre-XDR & XDR in MDR and ofloxacin and kanamycin resistance in non-MDR M. tuberculosis isolates. Tuberculosis. 2012;92:404–6. [PubMed] [Google Scholar].

Sloan DJ, Lewis JM. Management of multidrug-resistant TB: Novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg. 2016;110(3):163–172. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
DOI: 10.1093/trstmh/trv107

World Health Organization. The Global Tuberculosis Report: 2015. Geneva, Switzerland: WHO; 2015.
Available:http://www.who.int/tb/publications/global_report/gtbr2015_executive_summary.pdf
(Accessed 2016, Jan 18)

Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO Guidelines Approved by the Guidelines Review Committee: 2014 update. Geneva, Switzerland: WHO; 2014.
Available:http://www.who.int/tb/publications/pmdt_companionhandbook/en/
(Accessed 2016, Jan 18)

World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis: 2015 update. Geneva: WHO; 2015.
Available:http://apps.who.int/iris/bitstream/10665/174897/1/9789241549134_eng.pdf
(Accessed 25 Mar 2016)

Nair SA, Raizada N, Sachdeva KS, Denkinger C, Schumacher S, Dewan P, et al. Factors associated with tuberculosis and rifampicin-resistant tuberculosis amongst symptomatic patients in India: A retrospective analysis. PLoS One. 2016;11(2):e0150054. [PMC free article] [PubMed] [CrossRef] [Google Scholar].
DOI: 10.1371/journal.pone.0150054

CDC. Extensively drug-resistance tuberculosis information.
Available:http://www.cdc.gov/tb/topic/drtb/xdrtb.htm

DeLand FH, Wagner RN Jr. Early detection of bacterial growth with carbon-14 labeled glucose. Radiology. 1969;92: 154-155.

Roberts GD, Goodman NL, Heifets L, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear- positive specimens. J Clin Microbiol. 1983;18:689-696.

Siddiqi SH, Libonati JP, Middlebrook G. Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 1981;13:908-912.

Kent PT, Kubica GP. Public health microbiology, a guide for the level III laboratory. Centers for Disease Control, Division of Laboratory Training and Consultation, Atlanta, GA; 1985.

Siddiqi SH, Rüsch-Gerdes S. MGIT procedure manual. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland; 2006.

Salman H. Siddiqi, Sabine Rüsch-Gerdes., Foundation for innovative for new diagnosis; 2006.

Global Laboratory Initiative Advancing TB Diagnosis; 2014.
Available:mycobacteriology-laboratory-manual%20of%20Tuberculosis.pdf

World Health Organization. Policy Guidance on Drug Susceptibility Testing (DST) of Second Line Anti-tuberculosis Drugs. Geneva, WHO, (WHO/HTM/TB/2008.392); 2008.

Zink A, Sola C, Reischl U, Grabner W, Rastogi N, Wolf H, Nerlich A. Characterization of Mycobacterium tuberculosis complex DNAs from Egyptian Mummies by Spoligotyping. J Clin Microbiol. 2003;41(1):359-67.
DOI: 1128/JCM.41.1.359-367.2003
PMC: 149558
PMID: 12517873

Olusoji Daniel, Eltayeb Osman, et al. Pre-extensive drug resistant tuberculosis (Pre-XDR-TB) among MDR-TB patents in Nigeria. Global Advanced Research Journal of Microbiology (ISSN: 2315-5116). 2013;2(2).

Tasnim T, Tarafder S, Alam FM, Sattar H, Mostofa Kamal SM. Pre-extensively drug resistant tuberculosis (Pre-XDR-TB) among pulmonary multidrug resistant tuberculosis (MDR-TB) patients in Bangladesh. Journal of Tuberculosis Research. 2018;6:199-206.
Available:https://doi.org/10.4236/jtr.2018.63018

Sameer Adwani, et al. JKIMSU, prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among pulmonary multidrug resistant tuberculosis (MDR-TB) at a Tertiary Care Center in Mumbai. 2016;5(3). ISSN: 2231-4261.

Gosavi SV, et al. A step towards control of multidrug resistant tuberculosis: Hospital based study from Nashik, India. Community Medicine Department, Dr. Vasantrao Pawar Medical College, Hospital & Research Centre, Nashik.

Amita Jain, et al. Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates. Tuberculosis. 2012;92:404e406. Available:http://intl.elsevierhealth.com/journals/tube

Parul Singhal, et al. A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in North India. Indian J. Med. Res. 2016;143(3):341- 347.
DOI: 10.4103/0971-5916182625

Porwal C, Kaushik A, Makkar N, Banavaliker JN, Hanif M, Singla R, et al. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One. 2013;8(2):e55299.

Myneedu VP, Visalakshi P, Verma AK, Behera D, Bhalla M. Prevalence of XDR TB cases - a retrospective study from a tertiary care TB hospital. Indian J Tuberc. 2011;58(2):54-9.

Singh S, Sankar MM, Gopinath K. High rate of extensively drug- resistant tuberculosis in Indian AIDS patients. AIDS. 2007;21(17):2345-47.

Ajbani K, Rodrigues C, Shenai S, Mehta A. Can mutation detection accurately predict XDR- TB: Study from a tertiary care centre, India. J Clin Microbiol. 2011;49(4):1588- 90.

Rajasekaran S, Chandrasekar C, Mahilmaran A, Kanakaraj K, Karthikeyan DS, Suriakumar J. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients - a trend. J Indian Med Assoc. 2009;107(05):281-2, 284-6.

Kozinska M, Brzostek A, Krawiecka D, Rybczynska M, Zwolska Z, Augustynowicz-Kopec EMDR. Pre-XDR and XDR drug-resistant tuberculosis in Poland in 2000e2009. PneumonolAlergol Pol. 2011;79(4):278e87.

Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(1):113e9.